Results 231 to 240 of about 413,499 (385)

Cardiac Magnetic Resonance to Reclassify Diagnosis and Detect Cardiomyopathies in Hospitalized Patients with Acute Presentation. [PDF]

Life (Basel)
Tsampras T, Antonopoulos A, Kasiakogias A, Mika A, Kolovou A, Papadimitriou E, Lazaros G, Tsioufis K, Vlachopoulos C.   +8 more
europepmc   +1 more source

Idiopathic cardiomyopathy in infants [PDF]

, 1973
Rajkumar Doshi, K. V. Lodge
openalex   +1 more source

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF

ESC Heart Failure, EarlyView.
Abstract Aims Inter‐atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown.
Jerremy Weerts, Sanne G.J. Mourmans, Helena Lopez‐Martinez, Mar Domingo, Arantxa Barandiarán Aizpurua, Michiel T.H.M. Henkens, Anouk Achten, Josep Lupón, Hans‐Peter Brunner‐La Rocca, Christian Knackstedt, Antoni Bayés‐Genís, Vanessa P.M. van Empel   +11 more
wiley   +1 more source

α‑ketoglutarate protects against septic cardiomyopathy by improving mitochondrial mitophagy and fission. [PDF]

Mol Med Rep
Wu W, Ma Q, Li BT, Shi S, Guan GC, Wang JK, Xue BY, Liu ZW.   +7 more
europepmc   +1 more source

The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild‐type transthyretin amyloidosis

ESC Heart Failure, EarlyView.
Abstract Aims Wild‐type transthyretin cardiac amyloidosis (ATTRwt) is a cardiomyopathy causing myocardial hypoperfusion and impaired cardiac mitochondrial function. Trimetazidine is an antianginal agent used in patients with stable angina pectoris, which improves cardiac contractility and mitochondrial function.
Bertil Thyrsted Ladefoged, Anders Lehmann Dahl Pedersen, Anne Mette Dybro, Tor Skibsted Clemmensen, Julian Gillmore, Steen Hvitfeldt Poulsen   +5 more
wiley   +1 more source

Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy. [PDF]

Biomark Res
Cui H, Wang Y, Hua X, Han J, Mo H, Liu S, Wang H, Huang S, Zhao Y, Chen X, Zhao Q, Jia H, Chang Y, Song J.   +13 more
europepmc   +1 more source

Echocardiographic diagnosis and evaluation of cardiomyopathies: idiopathic hypertrophic subaortic stenosis, Chagas' heart disease and endomyocardial fibrosis [PDF]

, 1977
O Hernández-Pieretti
openalex   +1 more source

Cardiomyopathy

, 2006
Linda B. Lehmkuhl, John D. Bonagura
openaire   +2 more sources

Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy

ESC Heart Failure, EarlyView.
Katarzyna Holcman, Michał Tkaczyszyn
wiley   +1 more source

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

ESC Heart Failure, EarlyView.
Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin.
Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D. Avila, Geurys R. Rojas‐Marte   +7 more
wiley   +1 more source